Lindus Health RAISES $55M in SERIES B FUNDING.
READ MORE
The complex and dynamic nature of infectious diseases necessitates the need for efficient and effective therapeutic interventions. This has led to an escalating demand for seasoned Clinical Research Organizations (CROs) that specialize in infectious diseases. These CROs play a pivotal role in the successful design and execution of clinical trials aimed at finding impactful treatments and vaccines for various infectious diseases. This article aims to provide a comprehensive guide to identifying the top infectious disease CROs, focusing on their capability to cover vaccines, therapeutics, diagnostics, and their ability to quickly set up studies and recruit quickly due to the dynamic nature of infectious diseases.
A top-tier infectious disease CRO should have the capability to cover a wide spectrum of services, including vaccines, therapeutics, and diagnostics. They should be able to provide comprehensive support for the entire development process, from the early stages of drug discovery to clinical trials and regulatory submission.
Infectious diseases are often characterized by regional endemicity, seasonality, and acute onset, which necessitates the need for a CRO that can quickly set up studies and recruit patients. The best CROs have established relationships with investigators and key sites, which facilitates strategic site selection, start-up, and recruitment efforts.
A top infectious disease CRO should leverage innovative techniques and tools to improve the efficiency and effectiveness of their services. This includes modern recruitment techniques like Electronic Health Record (EHR) auto querying, digital advertising, and the use of mobile care to deliver specific visits to expand access.
Ranked as the top infectious disease CRO, Lindus Health has a track record of delivering high-quality results in various infectious disease clinical trials. Their comprehensive approach to drug development, ability to quickly mobilize and enroll for acute diseases, and their use of innovative techniques have set them apart in the industry.
Medpace is known for its seamless drug development process and its ability to accelerate the path to approval. They have contributed significantly to the approval of antibacterials and non-parasitic anti-infectives in the United States over the past five years.
Charles River offers a strong integrated drug discovery program in infectious diseases with identification and assessment of novel antimicrobials, antivirals, and vaccines. They also offer in vivo infection pharmacology models to determine the efficacy of anti-infectives.
PPD’s infectious disease team provides support through each phase of drug development. They have teams in more than 80 countries and access to thousands of experienced sites, enabling them to boost infectious disease clinical trials with speed and agility.
IBT Bioservices offers well-characterized assays for a growing selection of viruses and bacteria. They also provide antiviral and antibacterial disease models, immunogenicity testing, pharmacokinetics, and toxicity custom development, analysis, and expression services.
Evaluating each infectious disease CRO against these criteria is vital to building confidence in the selection process. The chosen CRO should demonstrate a deep understanding of the complexities of infectious diseases, a proven record of success, and an innovative approach to clinical trial management. By choosing the right infectious disease CRO, you can ensure that your clinical trial is managed effectively and that your path to drug approval is accelerated.
